Expert Interview
Discussing Corcept’s Lead Drug Candidate, Relacorilant + Nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
Ticker(s): CORTInstitution: Kaiser Permanente
- Gynecologist oncologist at Kaiser Permanente Riverside Medical Center (CA).
- Treats 10 LGSOC patients annually
- Familiar with investigational agents in gynecologic oncology
Please describe your clinical practice. How many patients with ovarian cancer? What percent of ovarian cancers become platinum-resistant and how do you measure benefit when proceeding with treatment?
Added By: elaineyCould you please tell us more about the mechanisms of platinum resistance, and the treatment options patients with PROC have? And what is platinum refractory disease?
Added By: elaineyCorcept reported significant improvement in PFS and DOR, 33% reduction in risk of death in their phase 2 study. Median OS was 13.9 months, compared to 12.2 months for women receiving nab-paclitaxel monotherapy. A subgroup analysis excluding platinum refractory disease patients and patients who received 4 prior lines of treatment shows significant improvement on both PFS and OS. Could you please discuss these results, and what it means for you?
Added By: elaineyAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
